A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
The "Embolic Protection Device Market Report, Forecast by Product, Application, Procedure, Material, Usage, End-User, Countries and Company Analysis, 2024-2032" report has been added to ...
Transcatheter aortic valve replacement (TAVR) is revolutionizing the treatment of aortic valve stenosis, offering a minimally invasive option for patients suffering from this heart condition. However, ...
Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...
US hospitals pulled back on their use of cerebral embolic protection during TAVI after publication of the PROTECTED TAVR results, a new analysis affirms. The proportion of procedures done with the ...
SANTA CRUZ, Calif., March 12, 2024 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as ...
Hosted on MSN
EmStop completes trial of embolic protection system
EmStop has completed the ‘Controlled Arterial Protection to Ultimately Remove Embolic Material’ (CAPTURE-1) early feasibility clinical study which assessed the EmStop embolic protection system. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results